-+ 0.00%
-+ 0.00%
-+ 0.00%

Valion Bio names Dean Zikria interim CEO

PUBT·09/23/2026 12:00:59
Listen to the news
Valion Bio names Dean Zikria interim CEO
  • Valion Bio named board member Dean Zikria interim CEO to steer strategy, including Entolimod development and partnership efforts.
  • Zikria previously held strategy and business development roles at Pfizer’s USD 7 billion US cardiovascular business.
  • Board appointed Thomas Jensen chair, also naming him chair of the compensation committee, replacing departing director Sheryle Bolton.
  • Jared Malbin took over as audit committee chair.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609230800ACCESSWRNAPR_____1225766) on September 23, 2026, and is solely responsible for the information contained therein.